Araştırma Makalesi
BibTex RIS Kaynak Göster

Yıl 2019, Cilt: 1 Sayı: 1, 32 - 36, 23.04.2019

Sadık Görkem Çevik , Mediha Tok Çevik , Müberra Akdoğan

Öz

Kaynakça

  • 1- Jager RD, Aiello LP, Patel SC,et al. Risks of intravitreous injection: a comprehensive review. Retina. 2004;24:676698.
  • 2- Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol. 2008;145:879-882.
  • 3- Abell RG, Kerr NM, Allen P, et al. Intravitreal injections: is there benefit for a theatre setting? Br J Ophthalmol. 2012;96:14741478.
  • 4- Van der Reis MI, La Heij EC, De Jong-Hesse Y, et al. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 2011;31:1449–1469.
  • 5- Elman MJ, Ayala A, Bressler NM, et al. Diabetic Retinopathy Clinical Research Network. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015;122:375-381.
  • 6- Sun Y, Qu Y. Comparison of intravitreal bevacizumab with intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to retinal vein occlusion: a Meta-analysis. Int J Ophthalmol. 2015;8(6):1234-1239.
  • 7- Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014 ;121:2473-2481.
  • 8- Arevalo JF, Jap A, Chee SP, et al. Endogenous endophthalmitis in the developing world. Int Ophthalmol Clin. 2010;50:173-187. 9- Dharan S, Pittet D. Environmental controls in operating theatres. J Hosp Infect. 2002;51:79-84.
  • 10- Lapid-Gortzak R, Traversari R, van der Linden JW, et al. Mobile ultra-clean unidirectional airflow screen reduces air contamination in a simulated setting for intravitreal injection. Int Ophthalmol. 2017; 37(1):131-137.
  • 11- The Royal College of Ophthalmologists, United Kingdom. The UK Guidelines for Intravitreal Injections Procedure 2009.
  • 12- Bande MF, Mansilla R, Pata MP, et al. Intravitreal injections of anti-VEGF agents and antibiotic prophylaxis for endophthalmitis: A systematic review and meta-analysis. Sci Rep. 2017;7:18088.
  • 13- Tabandeh H, Boscia F, Sborgia A, et al. Endophthalmitis associated with intravitreal injections: office-based setting and operating room setting. Retina. 2014; ;34:1823.
  • 14- McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina 2011;31:654–661.
  • 15- Bhavsar AR, Stockdale CR, Ferris FL III, et al. Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical anti biotics Arch Ophthalmol 2012;130:809–810.
  • 16- Cheung CS, Wong AW, Lui A, et al. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology 2012;119:1609– 1614.
  • 17- International Organization for Standardization, ISO 14644-1 (2013) Cleanrooms and associated controlled environments—Part 1: Classification of air cleanliness.
  • 18- Avery RL, Bakri SJ, Blumenkranz MS, et al. Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina. 2014; 34 Suppl 12: S1-S18.
  • 19- Schimel AM, Scott IU, Flynn HW Jr. Endophthalmitis after intravitreal injections: should the use of face masks be the standard of care? Arch Ophthalmol. 2011;129:1607-1609.
  • 20- Fineman MS, Hsu J, Spirn MJ, et al. Bimanual assisted eyelid retraction technique for intravitreal injections. Retina. 2013;33:1968-1970.
  • 21- Brynskov T, Kemp H, Sørensen TL. No cases of endophthalmitis after 20,293 intravitreal injections in an operating room setting. Retina. 2014;34(5):951-957.
  • 22- Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998;17: 857–872.
  • 23- Freiberg FJ, Brynskov T, Munk MR, et al. Low endophthalmitis rates after intravitreal anti-vascular endothelial growth factor injections in an operation room: A retrospective Multicenter Study. Retina 2017; 37(12): 23412346.

Intravitreal Injection Endophthalmitis Results: Two Different Rooms

Yıl 2019, Cilt: 1 Sayı: 1, 32 - 36, 23.04.2019

Sadık Görkem Çevik , Mediha Tok Çevik , Müberra Akdoğan

Öz

Purpose: To compare postoperative complication rates of  intravitreal injections (IVIs) when performed in dedicated rooms versus performed in standard surgical rooms.

Material and methods: Group 1 underwent IVIs in the operating room, Group 2 underwent IVIs in a dedicated room with high-efficiency particulate air filtering device (PFD) on mode (0.02 %). Postoperative complications, room particle counts were evaluated.

Results: A total of 13354 injections consisting of 652 females (48 %) and 680 males (52 %) who had undergone intravitreal injection were reviewed. Endophthalmitis was observed in a total of 3 injections (0,022%), 2 patients in the operating room (0.02%), and 1 patient in the dedicated room.

Conclusion: We found no difference between performing IVIs in a theatre versus in a dedicated room. 

Anahtar Kelimeler

hospital productivity endophthalmitis dedicated room intravitreal injections

Kaynakça

  • 1- Jager RD, Aiello LP, Patel SC,et al. Risks of intravitreous injection: a comprehensive review. Retina. 2004;24:676698.
  • 2- Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol. 2008;145:879-882.
  • 3- Abell RG, Kerr NM, Allen P, et al. Intravitreal injections: is there benefit for a theatre setting? Br J Ophthalmol. 2012;96:14741478.
  • 4- Van der Reis MI, La Heij EC, De Jong-Hesse Y, et al. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 2011;31:1449–1469.
  • 5- Elman MJ, Ayala A, Bressler NM, et al. Diabetic Retinopathy Clinical Research Network. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015;122:375-381.
  • 6- Sun Y, Qu Y. Comparison of intravitreal bevacizumab with intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to retinal vein occlusion: a Meta-analysis. Int J Ophthalmol. 2015;8(6):1234-1239.
  • 7- Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014 ;121:2473-2481.
  • 8- Arevalo JF, Jap A, Chee SP, et al. Endogenous endophthalmitis in the developing world. Int Ophthalmol Clin. 2010;50:173-187. 9- Dharan S, Pittet D. Environmental controls in operating theatres. J Hosp Infect. 2002;51:79-84.
  • 10- Lapid-Gortzak R, Traversari R, van der Linden JW, et al. Mobile ultra-clean unidirectional airflow screen reduces air contamination in a simulated setting for intravitreal injection. Int Ophthalmol. 2017; 37(1):131-137.
  • 11- The Royal College of Ophthalmologists, United Kingdom. The UK Guidelines for Intravitreal Injections Procedure 2009.
  • 12- Bande MF, Mansilla R, Pata MP, et al. Intravitreal injections of anti-VEGF agents and antibiotic prophylaxis for endophthalmitis: A systematic review and meta-analysis. Sci Rep. 2017;7:18088.
  • 13- Tabandeh H, Boscia F, Sborgia A, et al. Endophthalmitis associated with intravitreal injections: office-based setting and operating room setting. Retina. 2014; ;34:1823.
  • 14- McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina 2011;31:654–661.
  • 15- Bhavsar AR, Stockdale CR, Ferris FL III, et al. Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical anti biotics Arch Ophthalmol 2012;130:809–810.
  • 16- Cheung CS, Wong AW, Lui A, et al. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology 2012;119:1609– 1614.
  • 17- International Organization for Standardization, ISO 14644-1 (2013) Cleanrooms and associated controlled environments—Part 1: Classification of air cleanliness.
  • 18- Avery RL, Bakri SJ, Blumenkranz MS, et al. Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina. 2014; 34 Suppl 12: S1-S18.
  • 19- Schimel AM, Scott IU, Flynn HW Jr. Endophthalmitis after intravitreal injections: should the use of face masks be the standard of care? Arch Ophthalmol. 2011;129:1607-1609.
  • 20- Fineman MS, Hsu J, Spirn MJ, et al. Bimanual assisted eyelid retraction technique for intravitreal injections. Retina. 2013;33:1968-1970.
  • 21- Brynskov T, Kemp H, Sørensen TL. No cases of endophthalmitis after 20,293 intravitreal injections in an operating room setting. Retina. 2014;34(5):951-957.
  • 22- Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998;17: 857–872.
  • 23- Freiberg FJ, Brynskov T, Munk MR, et al. Low endophthalmitis rates after intravitreal anti-vascular endothelial growth factor injections in an operation room: A retrospective Multicenter Study. Retina 2017; 37(12): 23412346.
Toplam 22 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Göz Hastalıkları
Bölüm Makaleler
Yazarlar

Sadık Görkem Çevik

Mediha Tok Çevik

Müberra Akdoğan

Yayımlanma Tarihi 23 Nisan 2019
Kabul Tarihi 16 Nisan 2019
Yayımlandığı Sayı Yıl 2019 Cilt: 1 Sayı: 1

Kaynak Göster

APA Çevik, S. G., Tok Çevik, M., & Akdoğan, M. (2019). Intravitreal Injection Endophthalmitis Results: Two Different Rooms. Clinical and Experimental Ocular Trauma and Infection, 1(1), 32-36.
AMA Çevik SG, Tok Çevik M, Akdoğan M. Intravitreal Injection Endophthalmitis Results: Two Different Rooms. CEOTI. Nisan 2019;1(1):32-36.
Chicago Çevik, Sadık Görkem, Mediha Tok Çevik, ve Müberra Akdoğan. “Intravitreal Injection Endophthalmitis Results: Two Different Rooms”. Clinical and Experimental Ocular Trauma and Infection 1, sy. 1 (Nisan 2019): 32-36.
EndNote Çevik SG, Tok Çevik M, Akdoğan M (01 Nisan 2019) Intravitreal Injection Endophthalmitis Results: Two Different Rooms. Clinical and Experimental Ocular Trauma and Infection 1 1 32–36.
IEEE S. G. Çevik, M. Tok Çevik, ve M. Akdoğan, “Intravitreal Injection Endophthalmitis Results: Two Different Rooms”, CEOTI, c. 1, sy. 1, ss. 32–36, 2019.
ISNAD Çevik, Sadık Görkem vd. “Intravitreal Injection Endophthalmitis Results: Two Different Rooms”. Clinical and Experimental Ocular Trauma and Infection 1/1 (Nisan 2019), 32-36.
JAMA Çevik SG, Tok Çevik M, Akdoğan M. Intravitreal Injection Endophthalmitis Results: Two Different Rooms. CEOTI. 2019;1:32–36.
MLA Çevik, Sadık Görkem vd. “Intravitreal Injection Endophthalmitis Results: Two Different Rooms”. Clinical and Experimental Ocular Trauma and Infection, c. 1, sy. 1, 2019, ss. 32-36.
Vancouver Çevik SG, Tok Çevik M, Akdoğan M. Intravitreal Injection Endophthalmitis Results: Two Different Rooms. CEOTI. 2019;1(1):32-6.
 Kapak Resmi İndir

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License(CC BY-NC-SA 4.0)